CTLA-4 Antibody
Phase 2Small molecule
CTLA-4 Antibody is one of 31 small molecule programs targeting Immunochemotherapy. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
31 competitors in Prospective
#DrugCompanyPhaseTrials
1Tnkase
RocheApproved
Zeposia
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Venclexta
AbbViePhase 3
Nexavar
BayerPhase 3
Cytosar
TevaPhase 3
Xiidra
BBausch Health Americas, Inc.
Approved
Mulpleta
IItalian Network for Tumor Biotherapy Foundation
Approved
Beyfortus
BeiGenePhase 2
Imbruvica
PPharmacyclics LLC.
Phase 2
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunochemotherapy1 trial
Prospective1 trial
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07422753·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CTLA-4 Antibody. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- WWestern Regional Medical Center